Results 151 to 160 of about 756,649 (382)

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab [PDF]

, 2015
C. Hruska, Robert Bertoli, Yorke D. Young, Patrick H. Burkhart, Paul B. Googe   +4 more
openalex   +1 more source

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Ting Tsai, Jui Lan, Shang‐Hung Lin   +2 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Primary cutaneous lymphoma in a patient with mastocytosis: Is there an association? [PDF]

JAAD Case Rep, 2023
Kincaid CM, Phong C, Arnold JD, Fan X, Lee BA, Mesinkovska NA.   +5 more
europepmc   +1 more source

Multicentric B-cell lymphoma in a pygmy goat [PDF]

, 2016
A six-year-old, male pygmy goat was referred with a sudden onset of peripheral lymphadenopathy, which initially started as enlarged inguinal lymph nodes. Clinical examination showed swollen retropharyngeal, prescapular and inguinal lymph nodes. Serologic
Chiers, Koen, Deprez, Piet, Kolkman, Iris, Pardon, Bart, Ribbens, Stefaan, Van Aert, Marcel, Versnaeyen, Han   +6 more
core  

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Subcutaneous Panniculitis-like T-cell Lymphoma

Clinical Dermatology Review
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a primary, rare cutaneous T-cell lymphoma that resembles panniculitis and accounts for
Sonal Mandli, Rutu Harsh Oza, Amita H Sutaria, Bela J Shah   +3 more
doaj   +1 more source

Cutaneous Lymphoma and Antibody-Directed Therapies. [PDF]

Antibodies (Basel), 2023
Sernicola A, Ciolfi C, Miceli P, Alaibac M.   +3 more
europepmc   +1 more source

NF‐κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma

Cancer Science, EarlyView.
We identified a novel mechanism of resistance to histone deacetylase inhibitors (HDACi) in cutaneous T‐cell lymphoma (CTCL), mediated by NF‐κB activation. This finding highlights NF‐κB as a potential therapeutic target for overcoming HDACi resistance in CTCL.
Yuto Takahashi, Akihiro Kitadate, Sayaka Iwama, Wataru Kuroki, Ko Abe, Masahiro Yamada, Sho Ikeda, Hiroyuki Tagawa, Hideki Wakui, Masaki Hikida, Naoto Takahashi   +10 more
wiley   +1 more source